Is treatment with a luteinizing hormone-releasing hormone agonist justified in short adolescents?

In a 1953 editorial entitled “The Need for an Inhibitor of Gonadotropin,” Lawson Wilkins noted that a “method of suppressing the secretion of pituitary gonadotropins . . . might lead to the prevent...

[1]  J. Chaussain,et al.  Failure to improve height prediction in short-stature pubertal adolescents by inhibiting puberty with luteinizing hormone-releasing hormone analogue , 1993, European Journal of Pediatrics.

[2]  J. Yanovski,et al.  Treatment with a luteinizing hormone-releasing hormone agonist in adolescents with short stature. , 2003, The New England journal of medicine.

[3]  R. Gardiner,et al.  Altered cognitive function in men treated for prostate cancer with luteinizing hormone‐releasing hormone analogues and cyproterone acetate: a randomized controlled trial , 2002, BJU international.

[4]  W. Crowley,et al.  Is obesity an outcome of gonadotropin-releasing hormone agonist administration? Analysis of growth and body composition in 110 patients with central precocious puberty. , 1999, The Journal of clinical endocrinology and metabolism.

[5]  G. Cutler,et al.  Reproductive axis after discontinuation of gonadotropin-releasing hormone analog treatment of girls with precocious puberty: long term follow-up comparing girls with hypothalamic hamartoma to those with idiopathic precocious puberty. , 1999, The Journal of clinical endocrinology and metabolism.

[6]  R. Stratford,et al.  Are short normal children at a disadvantage? The Wessex growth study , 1997, BMJ.

[7]  R. Stratford,et al.  Psychological response to growth hormone treatment in short normal children. , 1996, Archives of disease in childhood.

[8]  A. Klibanski,et al.  A longitudinal evaluation of bone mineral density in adult men with histories of delayed puberty. , 1996, The Journal of clinical endocrinology and metabolism.

[9]  S. P. Campos,et al.  Short stature: a psychosocial burden requiring growth hormone therapy? , 1994, Pediatrics.

[10]  P. Hindmarsh,et al.  Therapeutic controversies: growth hormone (GH) treatment of non-GH deficient subjects. , 1994, The Journal of clinical endocrinology and metabolism.

[11]  J. Lantos,et al.  Ethical issues in growth hormone therapy. , 1989, JAMA.

[12]  W. Crowley,et al.  Therapeutic use of pituitary desensitization with a long-acting lhrh agonist: a potential new treatment for idiopathic precocious puberty. , 1981, The Journal of clinical endocrinology and metabolism.

[13]  T. Plant,et al.  Hypophysial responses to continuous and intermittent delivery of hypopthalamic gonadotropin-releasing hormone , 1978 .

[14]  L. Wilkins.  The need for an inhibitor of gonadotropin. , 1953, The Journal of clinical endocrinology and metabolism.